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A Mutation in the 50-UTR of IFITM5 Creates an In-Frame
Start Codon and Causes Autosomal-Dominant
Osteogenesis Imperfecta Type V with Hyperplastic Callus
Oliver Semler,2,11 Lutz Garbes,1,4,7,11 Katharina Keupp,1,4,8,11 Daniel Swan,3 Katharina Zimmermann,1
Jutta Becker,1 Sandra Iden,8 Brunhilde Wirth,1,4,7 Peer Eysel,5 Friederike Koerber,6 Eckhard Schoenau,2
Stefan K. Bohlander,9,10 Bernd Wollnik,1,4,8 and Christian Netzer1,*
Osteogenesis imperfecta (OI) is a clinically and genetically heterogeneous disorder associated with bone fragility and susceptibility to
fractures after minimal trauma. OI type V has an autosomal-dominant pattern of inheritance and is not caused by mutations in the
type I collagen genesCOL1A1 andCOL1A2. Themost remarkable and pathognomonic feature, observed in ~65% of affected individuals,
is a predisposition to develop hyperplastic callus after fractures or surgical interventions. To identify themolecular cause of OI type V, we
performed whole-exome sequencing in a female with OI type V and her unaffected parents and searched for de novo mutations. We
found a heterozygous de novomutation in the 50-untranslated region of IFITM5 (the gene encoding Interferon induced transmembrane
protein 5), 14 bp upstream of the annotated translation initiation codon (c.14C>T). Subsequently, we identified an identical hetero-
zygous de novo mutation in a second individual with OI type V by Sanger sequencing, thereby confirming that this is the causal muta-
tion for the phenotype. IFITM5 is a protein that is highly enriched in osteoblasts and has a putative function in bone formation and
osteoblast maturation. The mutation c.14C>T introduces an upstream start codon that is in frame with the reference open-reading
frame of IFITM5 and is embedded into a stronger Kozak consensus sequence for translation initiation than the annotated start codon.
In vitro, eukaryotic cells were able to recognize this start codon, and they used it instead of the reference translation initiation signal.
This suggests that five amino acids (Met-Ala-Leu-Glu-Pro) are added to the N terminus and alter IFITM5 function in individuals with
the mutation.Osteogenesis imperfecta (OI [MIM 166200, 166210,
259420, 166220, 610967, 613982, 610682, 610915,
259440, 613848, 610968, and 613849 for type I to XII of
the disease]) is a clinically and genetically heterogeneous
disorder associated with bone fragility and susceptibility
to fractures after minimal trauma. Some individuals with
OI also have hearing loss, dentinogenesis imperfecta,
hypermobility of joints, and/or blue sclera. The original
Sillence classification, introduced in 1979, uses clinical
and radiological features to differentiate between four
types: OI type I (mild nondeforming, with blue sclera),
type II (perinatal lethal), type III (progressive deforming),
and type IV (moderately deforming, with normal sclera).1
The majority of individuals with the clinical diagnosis
OI types I–IV have heterozygous mutations in one of
the two genes encoding the a chains of collagen type
1, COL1A1 (MIM 120150) and COL1A2 (MIM 120160).
OI types I–IV are inherited in an autosomal-dominant
manner, and the mutations result in quantitative and/or
qualitative defects in type 1 collagen production by osteo-
blasts.2–5
A substantial number of persons with OI do not have
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The Americare individuals with recessive mutations in a growing
list of genes that encode proteins involved in, among
other activities, the posttranslational processing or modifi-
cation of type 1 collagen (CRTAP [MIM 605497],6 LEPRE1
[MIM 610339],7 PPIB [MIM 123841],8 and BMP1 [MIM
112264]9,10), the final quality control of procollagen for-
mation (SERPINH1 [MIM 600943]11 and FKBP10 [MIM
607063)]12), or osteoblast differentiation (SP7/OSX [MIM
606633]13).14 The molecular pathomechanism leading to
OI in individuals with recessive mutations in SERPINF1
(MIM 172860) is currently unclear.15,16
In 2000, a COL1A1/2-mutation-negative group of in-
dividuals with autosomal-dominant OI was delineated.
These individuals had been classified as having OI type
IV, but had some clinical features clearly distinguishing
them from other persons with OI.17 They were then cate-
gorized as having OI type V. The most remarkable and
pathognomonic feature of OI type V, observed in approxi-
mately 65% of affected individuals, is a predisposition to
develop a hyperplastic callus after fractures or surgical
interventions, predominantly in long bones.18 Other fea-
tures are a radiodense band at the growth plate and in-
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Figure 1. Pictures of the Affected Individuals Enrolled in the
Study
(A) Radiograph of the femur of proband 2, showing a thickening of
the cortical bone on the medial side (arrows) and a hyperplastic
callus at the distal part of the thigh (asterisks).
(B) Radiograph of the lateral spine of proband 2 with signs of
vertebral fractures and wedge-shaped and biconcave deformities
(arrows).
(C) Radiograph of the right thigh of proband 1 at the age of 2.6
years, showing a hyperplastic callus. At the distal end of the femur,
a metaphyseal band (arrow), which is a typical sign of OI type V, is
visible. As a result of dislocation of the bone after a fracture, a
surgical treatment involving the insertion of two rods was neces-
sary. (D) Photograph documenting the swelling of the right thigh
of proband 1.characteristics are not consistently found in all individuals
with OI type V. On polarized light microscopy in individ-
uals with OI type V, an irregular pattern of bone lamella-
tion is seen. Dentinogenesis imperfecta and blue sclera
have not been observed, and there is no evidence for
altered collagenmigration in gel electrophoresis. The path-
ogenesis of OI type V is unknown.
In our specialized unit for children with OI at the Chil-
dren’s Hospital of the University of Cologne, we have
treated one girl (proband 1) and one boy (proband 2)
with the classical clinical diagnosis OI type V. Their diag-
noses were based on the fact that both had displayed radio-
logically confirmed episodes of hyperplastic callus forma-
tion after low-trauma fractures (Figure 1). In proband 1,
there was also a metaphyseal band visible on the distal
femur; such a band is another typical radiological finding
in individuals with OI V (Figure 1C). In proband 2, callus
formation in the tibia developed without a severe fracture,
and a biopsy excluded an osteosarcoma. The histological
report confirmed reactive callus tissue without signs of
malignancy. Neither of the children had a calcified interos-
seus membrane of the forearm.
The two children exhibited similar clinical symptoms
and disease severity, initially classified as OI type IV. There
were no intrauterine fractures reported, and birth length
and weight were normal. Dentinogenesis imperfecta was
not present, and there were no clinical signs of hearing
impairment. The sclerae were grayish, and no ophthalmo-
logical problems were detected. Both children had recur-
rent fractures of long bones and vertebral compression
fractures with resulting wedge-shaped vertebrae, indi-
cating generally reduced bone stability. Bone mineral
density was below the normal range, and both children
developed slight bowing of the extremities and short
stature during childhood. They were able to walk short
distances. For longer distances, they were dependent on
a wheelchair or walking aids.
The clinical findings with regard to the two children
are summarized in Table 1. No organ system other than
the skeletal system was affected. We did not perform
biochemical collagen analyses or molecular tests to ex-
clude mutations in genes known to be involved in the
pathogenesis of other OI types. The parents of the af-
fected children were healthy, nonconsanguineous, and of
German descent, and they had no overt signs of reduced
bone mineral density and no history of previous fractures.
DXA measurements have not been performed in the
parents. There were no other family members affected
by OI. Thus, the family histories were compatible with
underlying heterozygous de novo mutations in an as-yet-
unknown autosomal gene of the two affected children.
To identify the molecular cause of OI type V, we decided
to perform whole-exome sequencing in proband 1 and her
unaffected parents and to search for de novo mutations.
The study was approved by the ethics committee of the
Ludwig-Maximilians University of Munich, and written
informed consent was obtained from the probands’350 The American Journal of Human Genetics 91, 349–357, August 1parents. We used Agilent SureSelectXT All Exon V4 target
enrichment and 100 bp paired-end runs on an Illumina
HiSeq 2000 according to the manufacturers’ protocols.
Across the three samples the mean target coverage was0, 2012
Table 1. Clinical Features of Two Children with Osteogenesis
Imperfecta Type V
Clinical Findings Proband 1 Proband 2
Disease severity moderate moderate
OI typea V V
Age at first
presentation
1 year 7 months 8 years 7 months
Time of follow up 3 years 2 months 6 years 6 months
Hyperplastic-callus
formations after fractures
before bisphosphonate
treatment
yes yes
Age at start of
bisphosphonate
treatment
1 year 7 months
(iv. neridronate)
9 years 9 months
(oral residronate)
Birth length and
birth weight
normal normal
Confirmed prenatal
fractures
no no
Age at first
nontraumatic
fracture
5 months 18 months
Color of sclera normal normal
Dentinogenesis
imperfecta
no no
Hypermobility
of joints
no no
Hearing impairment no no
Old fractures
of extremitiesc
yes yes
Spine abnormalitiesc wedge-shaped
vertebrae
biconcave
vertebrae
Scoliosis no no
Calcified membrane
interossea
no no
Metaphyseal bands yes no
Anterior dislocation of
the radial head
no no
Severe bowing of
extremities (not due
to fractures)
no no
Age and region of first
fracture with hyperplastic
callus formation
8 months,
right femur
1 year 10 months,
forearm
Reduced joint mobility
due to callus formations
yes yes
Weight at first visit
kg/BMI (SD) [age]
7.3/15.3 (0.8)
[1.6 years]
25.8/16.5 (0.1)
[8.6 years]
Weight at last visit
kg/BMI (SD) [age]
12.9/14.0(1.0)
[4.8 years]
45.0/18.9 (0.4)
[15.1 years]
Length at first visit
cm (SD) [age]
69 (2.1) [1.6 years] 123 (1.8) [1.6 years]
Length at last visit
cm (SD) [age]
96 (2.8)
[4.8 years]
154 (2.4)
[15.1 years]
Retarded gross
motor functions
delayed standing
and walking
no
Table 1. Continued
Clinical Findings Proband 1 Proband 2
Mobility at last visit
if not limited by
fractures (BAMFb)
7 9
Intelligence normal normal
Serum calcium levelc normal normal
Serum alkaline
phosphatasec
normal elevated
Serum procollagen type
1 C-peptidec (marker
for osteoblastic activity)
not measured normal
Urinary
deoxypyridinolinec
(marker for osteoclastic
activity)
elevated elevated
First available bone
density, DXA ap spine
(z score) before
bisphosphonate
treatment
3.3 2.8
Last available bone
density, DXA ap spine
(z score) during
bisphosphonate
treatment
1.9 3.0
Period between
DXA measurements
2 years 2 months 6 years 6 months
Abbreviations are as follows: DXA, dual-energy X-ray absorptiometry; ap, ante-
rior-posterior; BMI, body mass index; SD, standard deviation.
aAccording to the expanded Sillence classification.17
bBrief assessment of motor function.19
cAt first presentation.
The Americ593, and on average, 84% of bases were covered to a
minimum depth of 20. Data were analyzed in Oxford
Gene Technology’s exome analysis pipeline. Briefly, reads
were aligned to the reference GRCh37 using bwa 0.61.20
Local realignment was performed around indels with
the Genome Analysis Toolkit (GATK v1.4).21 Optical and
PCR duplicates were marked in BAM files with Picard
1.62. Original HiSeq base quality scores were recalibrated
with GATK TableRecalibration, and variants were called
with GATK UnifiedGenotyper. We hard filtered indels
and SNPs according to the Broad Institute’s best-practice
guidelines (available online) to eliminate false-positive
calls. Variant annotation was done with a modified version
of ENSEMBL’s Variant Effect Predictor.22
To determine de novo mutations in the proband, we as-
sessed violations of the Mendelian inheritance rules in the
trio by using GATK SelectVariants.21 A Mendelian viola-
tion was scored if the child’s genotype differed unexpect-
edly from that of the known parental genotypes at the
same position. This captured positions in which the child
(1) harbors an allele that is not present in either parent or
(2) is homozygous for an allele present in one but not both
parents. To be called as a Mendelian violation, the geno-
type in the proband and both parents needed to have
a minimum genotype QUAL score of 50. QUAL scores arean Journal of Human Genetics 91, 349–357, August 10, 2012 351
calculated in the genotyping phase and are the Phred-
scaled probability that the polymorphism exists at this
site given the underlying sequencing data. The value will
increase with greater depth of coverage at the genotype
position. All but one of the called Mendelian inconsistan-
cies had read depths of >20 in the proband at the given
positions.
Sixteen genes with autosomal variants were thought to
contain Mendelian violations. Eleven of the 16 variants
were novel, i.e., they were not annotated in dbSNP132,
and these were analyzed inmore detail. Manual inspection
of the genotypes at the read-level revealed that three of the
genes with Mendelian violations that were associated with
point mutations did not result from the detection of a de
novo variant that was detected in the proband but absent
in both parents. Rather, they resulted from a putative
reversion of this sequence to the reference sequence in
the proband for whom one parent was homozygous
nonreference. These variants were discarded. Three other
Mendelian violations associated with indel positions
were rated as artifacts as a result of inconsistencies in the
genotype calls in one or both of the parents, a common
problem in the course of indel calling in lower-coverage
regions. None of the six variants that were discarded
affected the coding region of a transcript or a gene with
a known function in bone metabolism.
The remaining five variants were followed up by
Sanger sequencing of genomic DNA of the proband and
her parents. Only one of these variants, a heterozy-
gous C>T transition in the 50-UTR of IFITM5 (the gene
encoding Interferon induced transmembrane protein 5;
NM_00102595.1), affected the transcribed region of a
gene, and only two of the candidates were located within
genes that have a known function in bone homeostasis:
an intronic heterozygous A>C variant in RUNX1 (MIM
151385, NM_001754.4), located 1307 bp downstream of
exon2, and the IFITM5 variant. Sanger sequencing revealed
that three variants, including the intronic RUNX1 variant,
were false positives. That the RUNX1 variant was a false
positive is well compatible with the whole-exome
sequencing data; the RUNX1 variant call was error prone
because of low coverage (103) in the proband and the vari-
ant’s genomic location within a repeat region adjacent to
a deletion. Twovariantswere confirmedby Sanger sequenc-
ing as trueheterozygous denovomutations in theproband:
a variant c.6620-32_-34del in intron 18 of KIAA0947
(NM_015325.1), encoding a protein of unknown function,
and the IFITM5 50-UTR variant, located 14 bp upstream of
the annotated translation initiation codon of the gene.
The algorithms Splice View23 and Spliceport24 did not
predict that the intronic variant c.6620-32_-34del in
KIAA0947 would alter the adjacent splice acceptor site.
Therefore, a single de novo mutation in proband 1 re-
mained as a strong candidate for causing the phenotype:
the heterozygous variant c.14C>T in IFITM5 (Figure 2A
and Figure S1). This variant is located in the transcribed
region of a gene that encodes a protein with a function352 The American Journal of Human Genetics 91, 349–357, August 1in bone. Sanger sequencing of both coding IFITM5 exons
identified no other mutation in the proband. Primer
details are available upon request. As a next step, we per-
formed Sanger sequencing of the IFITM5 50-UTR and
both coding exons on genomic DNA samples of pro-
band 2 and his unaffected parents. Intriguingly, this indi-
vidual was heterozygous for the same 50-UTR mutation
c.14C>T, that we had identified in proband 1, whereas
both parents were homozygous for the reference sequence
at this site (Figure 2B). Again, no other mutation was de-
tected in the coding region of IFITM5 in the proband. We
confirmed paternity in both proband-parent trios by
genotyping 11 microsatellite markers (data not shown;
correct paternity in the first proband-parent trio can also
be derived from the low number of Mendelian violations
in the inheritance of variants). To exclude that this 50-
UTR sequence alteration represents a polymorphism, we
referred to the Exome Variant Server (NHLBI Exome
Sequencing Project [ESP], Seattle, WA). The genomic
position mutated in the two children with OI type V
(chr11:299,504 in hg19) was covered in more than
5,150 individuals of European American and African
American descent with an average read depth of 14-fold.
None of these individuals displayed the IFITM5 mutation
c.14C>T.
The de novo mutation rate in humans is ~1.13 108 per
position per haploid genome, and there are on average 70
new mutations arising in the diploid genome per genera-
tion and 0–3 de novo mutations detectable in the approx-
imately 50 MB of genomic DNA covered by a typical
whole-exome sequencing project.25–27 Therefore, a conser-
vative estimate that takes into account the fact that the
IFITM5 mutation affects a hypermutable cytosine-phos-
phate-guanine (CpG) dinucleotide would be that the likeli-
hood to detect identical de novo mutations in two individ-
uals with the same phenotype by chance is below 53 106.
We concluded that the IFITM5 mutation c.14C>T is the
molecular cause of OI type V in both affected children.
IFITM5 (alternatively called Bone-restricted interferon-
induced transmembrane protein-like protein [BRIL]) is
highly enriched in osteoblasts.28–30 Its function hasmainly
been studied in mice and rats. In these animals, Ifitm5
expression peaks during osteoblast maturation around the
early mineralization stage,28,29 suggesting a role in bone
formation.Mouse IFITM5has a similarity of 88% to human
IFITM5.28 The expression pattern of Ifitm5 during embry-
onal development is similar to that observed for Osterix
(Sp7),29 the human ortholog of which is mutated in a rare
autosomal-recessive form of OI.13 The available expression
data from adult rodents argue for a role of Ifitm5 not only
during bone formation in embryogenesis but also during
postnatal development. In Ifitm5/ mice, the long bones
are 15%–25% shorter at birth than in Ifitm5þ/ mice, and
they are sometimes severely bent, a symptom that par-
tially resolves by adulthood.31 However, bone morpho-
metric parameters for the tibiae did not differ significantly
between Ifitm5/ and Ifitm5þ/ mice, suggesting that loss0, 2012
Figure 2. Confirmation of the Heterozy-
gous 50-UTR IFITM5 Mutation in the Two
Proband-Parent Trios and Prediction of
Its Impact on IFITM5
(A) Validation of the IFITM5 mutation
in the 50-UTR by Sanger sequencing of
genomic DNA isolated from peripheral
blood. Electropherograms of proband 1
and her parents are shown. The position
of the heterozygous c.14C>T mutation
is indicated by the red arrow. Themutation
is clearly absent in both parents, confirm-
ing its de novo occurrence in proband 1.
The bases marked in yellow indicate the
position of the reference ATG; numbers
indicate the distance to the reference ATG.
(B) Identification of the identical IFITM5
c.14C>T mutation in proband 2. Elec-
tropherograms obtained by Sanger se-
quencing of genomic DNA of proband
2 and his parents are shown. Again,
the mutation is absent in both parents,
thereby proving its de novo occurrence.
The bases marked in yellow indicate the
position of the reference ATG; numbers
indicate the distance to the reference ATG.
(C) Comparison of the ideal Kozak
sequence [A/G]XXATGG with the refer-
ence ATG of IFITM5 and with the newly
formed upstream ATG at position 14. In
the left part of the diagram, the align-
ment of the mutated 50-UTR of IFITM5
is given, and the alignment of the refer-
ence ATG is depicted on the right. Match-
ing bases between the Kozak sequence
and the genomic DNA are connected by
dashed lines, and the respective ATG
codons are underlined. The position of
the c.14C>T mutation is highlighted in
yellow.
(D) Predicted protein structure of the
altered IFITM5. Both transmembrane do-
mains are marked in yellow, and the
helical intracellular domain is highlighted
in orange. Numbers indicate the amino
acids flanking individual domains. The 5
amino acids that would be added by the
c.14C>T mutation are marked in red.
The blue and gray boxes indicate the acetyl
residue predicted to be added to the wild-
type and altered protein, respectively.of Ifitm5 has no effect on bone mass. Increased bone
fragility or hyperplastic-callus formation has also not been
reported for Ifitm5-deficient mice. Other bone deficiencies
observed innewbornmice, such as a less-calcifiedmandible
and a thinner cranium, disappeared after 5weeks. The exact
function of IFITM5 in the process of bone formation, callus
formation, and osteoblast maturation remains to be eluci-
dated. In any case, the available experimental data for the
protein argue for a specific function in bones and are there-
fore well compatible with our genetic finding that muta-
tions in IFITM5 cause OI type V.
50-UTR mutations such as the one we identified in
IFITM5 can affect gene expression and protein translation
in multiple ways.32 Among these are aberrant splicing and
an altered mRNA secondary structure disrupting properThe Americtranslation. We found no evidence for such effects of the
IFITM5 c.14C>T mutation when we used the algorithms
Splice View,23 Spliceport,24 and RNA fold.33 An obvious
consequence of the heterozygous mutation in the 50-UTR
of IFITM5 is that it introduces an ATG upstream of the
annotated initiation codon for the gene. This upstream
ATG is in frame with the IFITM5 reference open-reading
frame (ORF). In general, eukaryotic translation initiation
begins at the first AUG embedded into the Kozak
consensus sequence [A/G]-XX-AUGG.34,35 To test whether
the AUG formed by the IFITM5mutation is embedded into
such a Kozak sequence, we used the DNA TIS Miner
and the ATGpr algorithms.36 Both algorithms predicted
the AUG created by the mutation to be a stronger start
codon than the reference AUG (Figure 2C), implying thatan Journal of Human Genetics 91, 349–357, August 10, 2012 353
Figure 3. Functional Assay for the c.14C>T Mutation
HEK293T cells were cultured in Dulbecco’s Modified Eagle Media
(DMEM, Life Technologies, Darmstadt, Germany) containing
10% fetal bovine serum (FBS, Life Technologies, Darmstadt,
Germany) and antibiotics. FuGENE HD transfection reagent
(Roche, Mannheim, Germany) was used for transient transfection
of these cells either with an IFITM5 wild-type (WT) expression
vector or with one of the construct variants containing the
50-UTR mutation c.14C>T. The cells were lysed after 30 hr, and
proteins were separated by SDS-PAGE with 4%–12% Bis-Tris gels
(Life Technologies, Darmstadt, Germany). Immunoblot analysis
with HA antibodies (Roche Diagnostics, Mannheim, Germany)
allowed detection of C-terminally tagged IFITM5 (upper panel).
Loading of equal protein amounts was confirmed by b-actin detec-
tion in the whole-cell lysates (lower panel).translation initiation in individuals with the mutation
would preferentially start upstream of the annotated
IFITM5 ORF. When this upstream AUG is used, five amino
acids (Met-Ala-Leu-Glu-Pro) are added to the N terminus of
the protein, thereby increasing its size from 137 amino
acids to 142 amino acids (Figure 2D).
IFITM5 contains two helical transmembrane domains
connected by an intracellular linker (Figure 2D). Both
the N and C termini are located at the outer site of
the plasma membrane. The MEMSAT37 script as well
as the DOMPRED38 algorithm predicted that IFITM5 pro-
tein structure would not be affected by such an ex-
tended N terminus. Next, we concentrated on posttrans-
lational modifications. The algorithms NetNGlyc39 and
NetOGlyc40 predicted no changes in glycosylation. The
TermiNator script41,42 predicted wild-type IFITM5 to
be acetylated at methionine 1 and the altered IFITM5
to be instead acetylated at the novel alanine at posi-
tion 2 (Figure 2D). Finally, we bioinformatically analyzed
whether the localization of the mutated IFITM5 might
be altered. Wild-type IFITM5 does not contain a signal
peptide guiding it to the plasma membrane, and neither
does altered IFITM5, as predicted by the algorithms Sig-
nalP43 and SecretomeP.44
Taken together, our bioinformatic analyses strongly
suggest that the IFITM5 mutation leads to the addition of
five amino acids to the N terminus of the protein and
predicts that the structure and localization of the mutated
protein is not impaired. To confirm in vitro that the
mutated 50-UTR sequence is recognized and used as a trans-
lation inititation signal in eukaryotic cells, we performed
immunoblotting with whole-cell lysates of transiently
transfected HEK293T cells overexpressing human IFITM5
reference mRNA, IFITM5 mRNA with the mutation
c.14C>T in the 50-UTR, or IFITM5mRNAwith this muta-
tion plus a second mutation replacing the reference AUG
by the leucine codon CUG (Figure S2). When the ex-
pression vector contained the reference 50-UTR sequence,
the C-terminally tagged IFITM5 protein displayed the ex-
pected molecular weight of approximately 15 kDa. The
mutation c.14C>T led to the production of IFITM5
with a slightly higher, but clearly distinct, molecular
weight (Figure 3). As demonstrated by the transfection of
the third construct lacking the reference IFITM5 start
codon, this increased molecular weight resulted from the
N-terminal extension of the protein by five amino acids.
Thus, the upstream translation initiation signal is used
instead of the IFITM5 reference start codon when both
are present in cis in eukaryotic cells.
Human disease-causing mutations that occur in the
50-UTR and create a translation initiation codon are highly
uncommon. There are a few published examples of mono-
genic disorders in which mutations introduce an up-
stream start codon that is out of frame with the annotated
ORF and that thereby reduces the level of the wild-type
protein.45,46 We performed a systematic search of the
Human Genome Mutation Database (HGMD)47 and of354 The American Journal of Human Genetics 91, 349–357, August 1the PubMed database and did not identify any 50-UTR
mutation that is known to cause disease through a novel
in-frame ATG upstream of the annotated translation
start site.
To assess whether the OI type V phenotype results from
an IFITM5 gain of function or loss of function, we
searched for copy-number variants and chromosomal
imbalances encompassing the IFITM5 locus in the Data-
base of Genomic Variants48 and the database DECI-
PHER.49 The IFITM5 locus is copy-number stable, but
two individuals (probands 250980 and 250982) anno-
tated in DECIPHER had a heterozygous genomic deletion
of 320 KB and 440 KB, respectively, which completely
deleted IFITM5 and more than a dozen other genes in
this region. The phenotypic description of these individ-
uals includes short stature in proband 250980 and short
phalanges, clinodactyly, and microcephaly in proband
250982 as the only skeletal features. The fact that the
two individuals obviously did not display bone fragility
or hyperplastic-callus formation indicates that haploinsuf-
ficiency of IFITM5 is rather unlikely to play a role in the
pathogenesis of OI type V. A dominant-negative effect
of the c.14C>T mutation cannot be formally excluded,
but such an effect is not supported by the phenotype
observed in Ifitm5 knock-out mice.29 From our point of
view, the most plausible pathomechanism underlying OI
type V is that the addition of five N-terminal amino acids
causes a gain of function of IFITM5 by altering the extra-
cellular ligand-binding properties of the receptor. Experi-
mental studies are needed to prove this hypothesis and
to dissect the molecular events leading to reduced bone
mineral density and hyperplasic-callus formation on the
cellular level.0, 2012
A gain-of-function pathomechanism for OI type V could
also explain the remarkable finding of an identical de novo
mutation in the two affected individuals. Such a gain of
function can be highly specific, thus limiting the muta-
tional spectrum observed for a disorder. A recent example
is the somatic activating mutation c.49G>A (p.Glu17Lys)
in the oncogene AKT1 (MIM 164730; NM_001014432.1).
This mutation has been identified in a mosaic form in 26
of 29 individuals with Proteus syndrome (MIM 176920),
a syndrome characterized by the overgrowth of connective
tissue, skin, brain, and other tissues.50 Sequencing IFITM5
in larger cohorts of individuals with OI type V will
clarify which proportion of cases is caused by themutation
c.14C>T.Supplemental Data
Supplemental Data include two figures and are available with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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